Zoetis Stock Price, News & Analysis (NYSE:ZTS)

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Zoetis announced a quarterly dividend on Thursday, May 16th. Investors of record on Friday, July 19th will be given a dividend of $0.164 per share on Tuesday, September 3rd. This represents a $0.66 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date of this dividend is Thursday, July 18th. View Zoetis' Dividend History.

Zoetis announced that its Board of Directors has authorized a share repurchase plan on Wednesday, December 12th 2018, which authorizes the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 4.7% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board of directors believes its stock is undervalued.

Zoetis Inc (NYSE:ZTS) posted its quarterly earnings results on Tuesday, August, 6th. The company reported $0.90 EPS for the quarter, beating the Zacks' consensus estimate of $0.82 by $0.08. The business earned $1.55 billion during the quarter, compared to analysts' expectations of $1.51 billion. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. Zoetis's revenue for the quarter was up 9.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.77 EPS. View Zoetis' Earnings History.

Zoetis is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Zoetis.

Zoetis updated its FY19 earnings guidance on Tuesday, August, 6th. The company provided EPS guidance of $3.53-3.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.49. The company issued revenue guidance of $6.18-6.28 billion, compared to the consensus revenue estimate of $6.19 billion.

15 equities research analysts have issued 1 year price targets for Zoetis' stock. Their forecasts range from $86.00 to $145.00. On average, they expect Zoetis' stock price to reach $121.4667 in the next twelve months. This suggests that the stock has a possible downside of 3.3%. View Analyst Price Targets for Zoetis.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.

Headlines about ZTS stock have been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Zoetis earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Zoetis.

Zoetis saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 4,326,600 shares, an increase of 9.4% from the July 31st total of 3,953,400 shares. Based on an average daily trading volume, of 2,010,000 shares, the short-interest ratio is presently 2.2 days. Currently, 0.9% of the shares of the stock are short sold. View Zoetis' Current Options Chain.

Some companies that are related to Zoetis include Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), Eli Lilly And Co (LLY), AbbVie (ABBV), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Bayer (BAYRY) and Allergan (AGN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Transocean (RIG), Gran Tierra Energy (GTE) and Och-Ziff Capital Management Group (OZM).

Zoetis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.68%), BlackRock Inc. (7.53%), BlackRock Inc. (7.51%), Morgan Stanley (2.78%), Polen Capital Management LLC (2.13%) and Nuveen Asset Management LLC (1.48%). Company insiders that own Zoetis stock include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.

ZTS stock was sold by a variety of institutional investors in the last quarter, including BNP PARIBAS ASSET MANAGEMENT Holding S.A., BlackRock Inc., BlackRock Inc., Mackenzie Financial Corp, AQR Capital Management LLC, Marshall Wace LLP, Marshall Wace North America L.P. and Price T Rowe Associates Inc. MD. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.

ZTS stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Stonehage Fleming Financial Services Holdings Ltd, Bank of New York Mellon Corp, Vanguard Group Inc., Natixis, Natixis, AKO Capital LLP and Ontario Teachers Pension Plan Board. View Insider Buying and Selling for Zoetis.

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZTS stock can currently be purchased for approximately $125.62.

Zoetis has a market capitalization of $59.99 billion and generates $5.83 billion in revenue each year. The company earns $1.43 billion in net income (profit) each year or $3.13 on an earnings per share basis. Zoetis employs 10,000 workers across the globe.View Additional Information About Zoetis.

The official website for Zoetis is http://www.zoetis.com/.

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]